![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 3 of 3. This is the beginning of the thread.
Posted by vince on March 12, 2001, at 0:00:59
There have been one or two posts lately asking about cortisol blockers or CRF antagonists. The following press release might be of some interest to you.
Vince
http://psychiatry.medscape.com/reuters/prof/2001/03/03.09/20010308drgd008.html
--------------------------------------------------------------------------------
Phase I Data Positive on CRF Receptor Antagonist for Depression, Anxiety
--------------------------------------------------------------------------------NEW YORK (Reuters Health) Mar 08 - Neurocrine Biosciences, of San Diego, said on Thursday that data from a phase I trial of its corticotropin releasing factor (CRF) receptor antagonist product for depression and anxiety indicate that the drug is well tolerated.
According to Neurocrine, the company believes that the drug blocks stress responses mediated by CRF, resulting in anti-anxiety and anti-depressant effects.
Additionally, the 48-patient single-dose study indicated rapid absorption, as well as good dose-proportionality and plasma half-lives of the CRF receptor antagonist that support a once-daily dosing schedule.
A 2-week, multi-dose, dose-escalating trial is planned to evaluate the safety and endocrine profiles of the compound, the company said. Phase II trials are expected to follow.
Posted by JohnX on March 12, 2001, at 5:07:39
In reply to Who was asking about CRF antagonists, posted by vince on March 12, 2001, at 0:00:59
> There have been one or two posts lately asking about cortisol blockers or CRF antagonists. The following press release might be of some interest to you.
>
> Vince
>
> http://psychiatry.medscape.com/reuters/prof/2001/03/03.09/20010308drgd008.html
> --------------------------------------------------------------------------------
> Phase I Data Positive on CRF Receptor Antagonist for Depression, Anxiety
> --------------------------------------------------------------------------------
>
> NEW YORK (Reuters Health) Mar 08 - Neurocrine Biosciences, of San Diego, said on Thursday that data from a phase I trial of its corticotropin releasing factor (CRF) receptor antagonist product for depression and anxiety indicate that the drug is well tolerated.
>
> According to Neurocrine, the company believes that the drug blocks stress responses mediated by CRF, resulting in anti-anxiety and anti-depressant effects.
>
> Additionally, the 48-patient single-dose study indicated rapid absorption, as well as good dose-proportionality and plasma half-lives of the CRF receptor antagonist that support a once-daily dosing schedule.
>
> A 2-week, multi-dose, dose-escalating trial is planned to evaluate the safety and endocrine profiles of the compound, the company said. Phase II trials are expected to follow.Hey that's good news. When would one expect a CRF-antagonist to potentially hit the market?
I hope these treatments also show promise especially for PTSD patients where dysfunction in the HPA axis is hoped to the best place to target for 1st line treatment.
-john
Posted by steve on March 13, 2001, at 1:26:19
In reply to Re: Who was asking about CRF antagonists, posted by JohnX on March 12, 2001, at 5:07:39
I think NRGN and NBIX are both either in Phase Is or getting there. DuPont and Novartis are also working on them, as is Pfizer.
With luck, we looking at 5 yrs, though that's only a 50% probability. I have been told that it is expected that they will be the first meds to really do anything for PTSD.
Hope this helps,
And keep your head up.
> > There have been one or two posts lately asking about cortisol blockers or CRF antagonists. The following press release might be of some interest to you.
> >
> > Vince
> >
> > http://psychiatry.medscape.com/reuters/prof/2001/03/03.09/20010308drgd008.html
> > --------------------------------------------------------------------------------
> > Phase I Data Positive on CRF Receptor Antagonist for Depression, Anxiety
> > --------------------------------------------------------------------------------
> >
> > NEW YORK (Reuters Health) Mar 08 - Neurocrine Biosciences, of San Diego, said on Thursday that data from a phase I trial of its corticotropin releasing factor (CRF) receptor antagonist product for depression and anxiety indicate that the drug is well tolerated.
> >
> > According to Neurocrine, the company believes that the drug blocks stress responses mediated by CRF, resulting in anti-anxiety and anti-depressant effects.
> >
> > Additionally, the 48-patient single-dose study indicated rapid absorption, as well as good dose-proportionality and plasma half-lives of the CRF receptor antagonist that support a once-daily dosing schedule.
> >
> > A 2-week, multi-dose, dose-escalating trial is planned to evaluate the safety and endocrine profiles of the compound, the company said. Phase II trials are expected to follow.
>
> Hey that's good news. When would one expect a CRF-antagonist to potentially hit the market?
>
> I hope these treatments also show promise especially for PTSD patients where dysfunction in the HPA axis is hoped to the best place to target for 1st line treatment.
>
> -john
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.